Macrophage-Targeted LNP Development

Macrophage-Targeted LNP Development

We develop macrophage-targeted LNPs through macrophage-tropic lipid design and surface ligand functionalization, providing end-to-end support from ligand selection and lipid synthesis to formulation, characterization, and delivery evaluation.

Macrophage-targeted LNPs are engineered to deliver nucleic acid and other payloads into macrophage populations with functional outcomes, rather than being passively cleared by them. Conventional LNPs are rapidly captured by the mononuclear phagocyte system and accumulate mainly in liver and spleen, where Kupffer cells and splenic red pulp macrophages take up particles efficiently but often without productive payload expression. Macrophage-targeted formulations counter this default behavior by combining receptor-directed ligands such as mannose, galactose derivatives, antibodies, and macrophage-subset peptides with lipid-intrinsic engineering approaches, including selective organ targeting (SORT) compositions and phosphatidylserine-based biomimetic designs.

BOC Sciences provides integrated targeted LNP development, covering targeting ligand synthesis and conjugation, ionizable and helper lipid screening, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support macrophage-directed delivery of mRNA, siRNA, miRNA, plasmid DNA, and genome-editing payloads across liver, spleen, lung, tumor, and plaque macrophage contexts, with the development scope adapted to the intended cell population and biological endpoint.

Schematic Diagram of Macrophage-Targeted Lipid NanoparticlesMacrophage-Targeted Lipid Nanoparticle Illustration

How Is Macrophage Targeting Achieved with LNPs?

Macrophage-targeted LNPs are lipid nanoparticles designed so that a defined macrophage population takes them up preferentially and productively. Targeting is achieved through two complementary layers. The first is surface ligand recognition: ligands displayed on the LNP surface bind receptors that are abundant or activation-specific on macrophages, triggering receptor-mediated endocytosis. The second is lipid-intrinsic and biomimetic targeting: particle composition is tuned so that the adsorbed protein corona or the particle surface itself mimics natural macrophage ligands, redirecting biodistribution toward macrophage-rich compartments.

Because macrophages are highly heterogeneous, the choice of targeting mechanism must match the intended cell population. The table below summarizes receptor–ligand pairs commonly used to direct LNPs to macrophages:

Macrophage ReceptorLigand or Design FeatureMacrophage-Targeting Relevance
Mannose receptor (CD206/MRC1)Mannose or mannosylated PEG-lipidsHighly expressed on alternatively activated (M2-like) macrophages, including profibrotic lung macrophages, SPP1+ tumor-associated macrophages, and Kupffer cells.
C-type lectin receptors (MGL1/2, Dectin-1)Galactose and glycolipid structuresRecognized on macrophage galactose-type lectins and pattern-recognition receptors, enabling subset-selective glycan targeting.
Scavenger receptors (SR-A, MARCO, Stabilin-2)Anionic or polyanionic surfaces, S2P peptideMediate uptake of anionic particles and peptide-targeted LNPs by plaque macrophages and splenic macrophages.
Tim-4 and MerTKPhosphatidylserine on the particle surfaceMimics the "eat-me" signal of apoptotic bodies, driving selective uptake by phagocytic macrophages.
Folate receptor-β (FR-β)Folate ligandsUpregulated on activated macrophages in inflammatory and autoimmune contexts.
Corona-mediated recognition (β2-GPI, ApoE)Anionic SORT lipids, lipid headgroup tuningShapes the protein corona so that spleen CD169+ red pulp macrophages or other macrophage compartments preferentially capture the particles.

BOC Sciences develops macrophage-targeted LNPs by matching these recognition mechanisms to the payload, the tissue environment, and the required functional readout, so that uptake translates into measurable gene silencing, protein expression, or cell-state modulation rather than simple particle clearance.

BOC Sciences Macrophage-Targeted LNP Development Services

Our development services integrate lipid chemistry, ligand engineering, nanoparticle formulation, and biological evaluation to address the specific challenges of macrophage delivery. Projects can start with an existing LNP formulation, a candidate targeting ligand, or only a defined macrophage-delivery objective. We customize the development scope according to payload properties, target-cell characteristics, and the intended administration route.

Macrophage-Selective Lipid Design and Screening

We investigate how ionizable lipid structures and supporting lipid components influence macrophage interactions, intracellular delivery, and biodistribution toward macrophage-rich organs.

  • Ionizable Lipid Structure Screening: Compare headgroup chemistry, pKa range, hydrophobic tail branching, and linker structures to identify candidates that favor productive delivery in macrophage models such as bone marrow-derived macrophages, RAW264.7 cells, and human monocyte-derived macrophages. Our LNP ionizable lipid optimization services support structure-guided screening.
  • Helper Lipid and Sterol Balance: Adjust phospholipid identity (for example, DOPE versus DSPC content), cholesterol and phytosterol fractions, and lipid molar ratios to control membrane fusion behavior and macrophage uptake.
  • SORT-Style Composition Engineering: Introduce permanently charged or glycolipid components to redirect particles toward spleen, lung, or specific macrophage compartments, with each design compared against a matched conventional formulation.

Macrophage-Targeting Ligand Engineering and Surface Functionalization

We develop ligand-functionalized LNPs that engage macrophage receptors with controlled density and accessibility. Ligand identity, attachment chemistry, spacer design, and surface display are optimized together.

  • Glycan, Antibody, and Peptide Ligands: Prepare mannosylated and galactosylated lipid anchors, macrophage-marker antibodies or fragments, and subset-recognizing peptides, and incorporate them by pre-formulation or post-insertion routes.
  • Conjugation Chemistry and Ligand Density: Optimize linker chemistry, lipid anchors, spacer length, coupling conditions, and ligand input through appropriate nanoparticle conjugation services, then quantify ligand exposure on the finished particles.
  • Antibody-Displayed Designs: Develop antibody- and fragment-displayed LNPs directed toward macrophage surface markers, with orientation and density tuned through our antibody conjugated lipid nanoparticles workflow.

Payload-Compatible LNP Formulation and Process Optimization

We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended macrophage-delivery application.

  • Payload Encapsulation: Optimize lipid-to-payload ratios, aqueous and organic phases, mixing conditions, and formulation pH for different nucleic acid and small-molecule payloads through customized lipid nanoparticle formulation.
  • Multi-Payload and Co-Delivery Designs: Develop single-particle co-formulations, for example siRNA plus mRNA, immunostimulatory oligonucleotides plus silencing payloads, supported by our experience in co-encapsulation of multiple payloads in LNPs.
  • PEG-Lipid and Ligand Balance: Adjust PEG-lipid content and ligand incorporation to balance colloidal stability against macrophage receptor accessibility, and compare pre-mixing versus post-insertion incorporation sequences.
  • Process Parameter Optimization: Refine lipid concentration, microfluidic mixing conditions, flow-rate ratios, and post-formulation processing through LNP process optimization.

Physicochemical, Cellular, and In Vivo Evaluation

We evaluate the physicochemical properties of candidate LNPs alongside macrophage-cell delivery and tissue-level performance to identify whether formulation improvements translate into functional payload delivery.

  • Particle Characterization: Analyze particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and payload integrity using appropriate lipid nanoparticle characterization methods.
  • Macrophage-Cell Uptake: Compare cellular association and internalization in selected macrophage and myeloid-cell models using nanoparticle cellular uptake testing, with receptor-positive and receptor-negative comparisons.
  • Functional Delivery: Evaluate reporter expression, target-gene knockdown, cytokine output, or genome-editing outcomes according to the payload and research objective.
  • Tissue-Level Evaluation: Compare macrophage-compartment delivery against off-target organ exposure through nanoparticle cellular and in vivo evaluation, including flow-cytometric subset analysis of recovered tissue cells.

Macrophage-Targeting Strategies for Lipid Nanoparticles

Macrophage-targeted LNPs can be developed through receptor-mediated ligand recognition, biomimetic surface engineering, or intrinsic lipid composition modification. The selection of a targeting strategy depends on macrophage subtype, receptor expression, administration route, and payload requirements. BOC Sciences supports the development and comparative evaluation of the following approaches.

Glycan-Functionalized LNPs (Mannose and Galactose Ligands)

Glycan-functionalized LNPs use carbohydrate ligands to interact with lectin receptors expressed by selected macrophage populations. Mannose is particularly relevant to CD206-mediated uptake, whereas galactose can interact with macrophage galactose-type lectin CD301. The targeting outcome depends on receptor abundance, ligand presentation, and the distribution of these receptors across different tissue cells.

  • Mannose-Functionalized LNPs: Incorporate mannose-conjugated cholesterol or mannose-bearing PEG-lipids into the LNP composition. Mannose can interact with CD206-positive macrophages, including selected Kupffer cell and tumor-associated macrophage populations. A 2025 study demonstrated that mannose-conjugated cholesterol LNPs enhanced mRNA delivery to Kupffer cells and liver sinusoidal endothelial cells, with surface-accessible mannose and PEG-lipid shedding influencing targeting performance.
  • Galactose-Functionalized LNPs: Introduce galactose-containing lipid conjugates or glycan-bearing surface components to investigate interactions with CD301-positive macrophage populations. Galactose-functionalized liposomes have demonstrated receptor-dependent uptake in macrophage research, while additional studies have explored galactose-mediated recognition of M2-like tumor-associated macrophages. These findings provide a rationale for LNP development, although macrophage-selective galactose-LNP delivery requires formulation-specific validation.
  • Design Considerations: Optimize carbohydrate identity, ligand density, PEG spacer length, surface accessibility, and receptor expression. Evaluate possible interactions with other CD206- or CD301-expressing cells rather than assuming macrophage-exclusive recognition.

Research reference: Mannose-conjugated cholesterol LNPs for Kupffer cell delivery (Bioconjugate Chemistry, 2025); mannosylated spleen-targeted mRNA-LNPs for macrophage-associated delivery (ACS Biomaterials Science & Engineering, 2026).

Antibody-Functionalized LNPs for Macrophage Surface Markers

Antibody-functionalized LNPs use surface-displayed antibodies or antibody fragments to recognize selected macrophage-associated membrane proteins. This approach can provide an additional recognition layer beyond the natural phagocytic uptake of conventional LNPs, making it useful when a defined cell-surface marker is available.

  • F4/80-Directed LNPs: F4/80 is widely used as a macrophage-associated marker in murine research. Antibody-functionalized LNPs can be designed to recognize F4/80-positive populations and improve particle association and payload delivery. However, F4/80 is not a universal human macrophage marker, so alternative receptors must be selected for human-targeted systems.
  • CD163- and CD206-Directed LNPs: Antibodies or antibody fragments against selected surface-accessible receptors can be explored for macrophage populations associated with tissue remodeling, scavenging activity, or immunosuppressive tumor microenvironments. Target selection should account for receptor expression on non-target cells.
  • Surface Conjugation: Attach antibodies through reactive lipid anchors or functional PEG-lipids. Optimize antibody orientation, spacer length, conjugation conditions, and ligand density to maintain receptor accessibility while minimizing particle aggregation.
  • Functional Evaluation: Compare antibody-functionalized LNPs with unconjugated and isotype-control formulations to distinguish receptor-mediated targeting from nonspecific phagocytic uptake.

Research reference: A study screened 112 LNP formulations and subsequently conjugated an F4/80 antibody to the selected LNP surface for macrophage-targeted TAK1 siRNA delivery in a viral pneumonia model (Proceedings of the National Academy of Sciences, 2024).

Peptide-Functionalized LNPs for Macrophage-Subset Recognition

Peptide-functionalized LNPs use short recognition sequences or cell-penetrating peptides to improve interactions with selected macrophage populations. Peptides can be attached to lipid anchors or PEG-lipid conjugates, providing a flexible surface architecture for investigating macrophage-subset recognition and intracellular delivery.

  • M2-Associated Recognition Peptides: M2pep is a research peptide investigated for its preferential interaction with M2-like macrophages and tumor-associated macrophages. Its incorporation into a lipid-based delivery system can be explored when the objective is to improve delivery to immunosuppressive macrophage populations.
  • Cell-Penetrating Peptides: Introduce membrane-interacting or cell-penetrating peptide components to investigate cellular internalization, tissue penetration, and intracellular payload availability. These peptides can complement receptor-binding ligands but should not automatically be considered macrophage-specific.
  • Dual-Peptide Functionalization: Combine a macrophage-recognition peptide with a cell-penetrating component to investigate whether receptor association and intracellular delivery can be improved within one formulation.
  • Design Considerations: Optimize peptide sequence selection, lipid-anchor chemistry, spacer length, surface density, and peptide stability. Compare the functional delivery of modified LNPs with non-targeted controls.

Research reference: M2 macrophage-targeting peptide-modified liposomes were investigated for enhanced uptake and antitumor activity of liposomal IFN-γ in a murine tumor model (Cytokine, 2025). This provides supporting evidence for peptide-mediated macrophage recognition in lipid vesicles; direct performance in conventional LNP formulations requires independent evaluation.

Lipid-Intrinsic and Biomimetic Targeting (SORT and Phosphatidylserine-Based Designs)

Lipid-intrinsic targeting modifies the composition and physicochemical characteristics of LNPs to influence organ distribution and interactions with phagocytic cells. Biomimetic designs can incorporate phosphatidylserine (PS), a natural membrane lipid associated with apoptotic-cell recognition, to promote interactions with phagocytes.

  • SORT-LNPs: Selective organ targeting (SORT) introduces an additional lipid component into a conventional LNP formulation to modify tissue distribution. Anionic lipid components have been used to shift mRNA delivery toward the spleen, whereas permanently cationic components can promote lung-associated delivery. Spleen-targeted SORT formulations can reach macrophages as well as B cells and T cells; therefore, organ enrichment should not be interpreted as macrophage-specific delivery without cell-level evaluation.
  • Phosphatidylserine-Containing LNPs: Incorporate PS into the lipid composition to mimic an apoptotic-cell recognition signal. PS can interact with phagocyte-associated recognition pathways and promote monocyte/macrophage-mediated nanoparticle uptake. This strategy is particularly relevant to spleen and lymph node delivery research.
  • Biomimetic Lipid Composition: Explore PS content, lipid headgroups, membrane packing, particle size, and surface charge to influence phagocyte recognition and cellular uptake.
  • Design Considerations: Compare organ distribution with cell-specific particle uptake and functional RNA expression. Evaluate potential interactions with neutrophils, monocytes, and other phagocytic populations alongside macrophages.

Research reference: PS-containing LNPs promoted monocyte/macrophage-mediated mRNA delivery to secondary lymphoid organs (Nano Letters, 2022); SORT-LNPs enabled composition-dependent tissue targeting for mRNA delivery and CRISPR-Cas gene editing (Nature Nanotechnology, 2020).

Which Macrophage-Targeting Strategy Fits Your LNP Project?

Share your target macrophage population, receptor information, payload, and intended administration route. BOC Sciences can help compare ligand-mediated, antibody-based, peptide-functionalized, and lipid-intrinsic targeting approaches to identify suitable development options.

Supported Payloads for Macrophage-Targeted LNPs

Macrophage-targeted LNPs have been investigated for different payload classes, particularly nucleic acids used to regulate macrophage gene expression, protein production, and functional states. BOC Sciences supports payload-specific formulation and encapsulation strategies, with the development approach selected according to cargo chemistry, intracellular destination, and desired biological response.

Payload TypeSupported Uses & Macrophage-Targeted LNP Development ConsiderationsRequest Information
Macrophage-Targeted LNP for mRNADesigned for transient expression of transcription factors, immune-modulating proteins, cytokines, and chimeric antigen receptors (CARs) in macrophages. Applications include macrophage reprogramming, tumor microenvironment modulation, and protein-expression research. Development focuses on mRNA integrity, encapsulation, intracellular release, and cell-specific protein expression. Recent studies have investigated mannose-functionalized LNPs and macrophage-targeted mRNA delivery for in situ CAR-macrophage programming. Supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
Macrophage-Targeted LNP for siRNASuitable for silencing macrophage-associated inflammatory and immunoregulatory genes. Published research has investigated siRNA against TAK1, c-Rel, IRF5, and SHP-1 in macrophage-related delivery systems. Development emphasizes cytosolic siRNA availability, target-gene knockdown, macrophage-subset selectivity, and functional changes in inflammatory signaling. Our lipid nanoparticles for siRNA delivery services support customized formulations and gene-silencing evaluation.Inquiry
Macrophage-Targeted LNP for CRISPR ComponentsCan be explored for targeted genome-editing research using Cas9 mRNA with guide RNA or Cas9 ribonucleoprotein (RNP) payloads. Formulation development considers co-encapsulation, cargo stoichiometry, RNA integrity, intracellular release, and editing activity in the intended macrophage population. Macrophage-specific editing requires direct validation rather than relying solely on organ-level delivery results. Our lipid nanoparticles for CRISPR RNP delivery services support related nucleic acid delivery development.Inquiry
Macrophage-Targeted LNP for Immunomodulatory Co-DeliveryDesigned for selected combinations of RNA payloads and immunomodulatory compounds. For example, macrophage-targeted mRNA-LNP research has explored combining CAR-encoding mRNA with an immune agonist to support macrophage programming. Development focuses on compatibility between lipid components and each payload, loading sequence, release behavior, and preservation of functional activity. Our LNP co-delivery services support the evaluation of multiple-payload formulations.Inquiry
Macrophage-Targeted LNP for Custom PayloadsDeveloped for other nucleic acids, selected hydrophobic compounds, or specialized payload combinations. We assess lipid-payload compatibility, encapsulation or incorporation methods, surface modification compatibility, payload retention, and macrophage-associated delivery performance. For hydrophobic cargo, our hydrophobic payload encapsulation in LNPs capabilities can support formulation development.Inquiry
Need a Macrophage-Targeted LNP for Your Specific Payload?

Tell us your payload, target macrophage population, and desired biological outcome. BOC Sciences can help select suitable lipid components, targeting ligands, and formulation conditions for your project.

Our Macrophage-Targeted LNP Development Workflow

Projects can begin with an existing LNP formulation, a candidate macrophage-targeting ligand, or a defined cell-specific delivery objective. We organize the development process into four practical stages and refine the formulation according to physicochemical and biological evaluation results.

Macrophage target and payload selection

1Define the Target Macrophage Population and Payload

We review the target tissue, macrophage population, species, receptor expression profile, payload class, and intended biological response. The target may be tumor-associated macrophages, Kupffer cells, alveolar macrophages, splenic macrophages, or activated inflammatory macrophages. These inputs determine the appropriate cellular models, candidate targeting ligands, and functional evaluation endpoints.

Lipid composition and targeting architecture selection

2Select Lipid Composition and Targeting Architecture

We propose candidate ionizable lipids, helper phospholipids, cholesterol, and PEG-lipid components, then compare suitable targeting architectures such as mannose, antibodies, peptides, PS-containing lipids, or SORT-based compositions. Ligand density, PEG shielding, and lipid ratios are optimized through structured LNP lipid ratio optimization services. Matched non-targeted LNPs are included to distinguish the contribution of the targeting modification from the intrinsic uptake of the carrier.

LNP formulation and characterization

3Formulate and Characterize Candidate LNPs

Candidates are prepared using selected mixing and formulation conditions and compared for particle size, PDI, zeta potential, morphology, ligand presentation, and payload retention. We refine lipid composition, mixing parameters, purification, and buffer exchange during formulation development. Additional nanoparticle intracellular localization detection can help investigate particle trafficking and payload distribution after cellular uptake.

Macrophage uptake and in vivo delivery evaluation

4Evaluate Macrophage Uptake and Functional Delivery

Selected formulations are evaluated in macrophage models using fluorescence imaging, flow cytometry, and payload-specific endpoints such as reporter expression, protein production, or gene knockdown. Nanoparticle in vivo distribution analysis can further compare tissue accumulation, macrophage localization, and off-target organ exposure. The resulting data support candidate ranking and the next formulation optimization cycle.

What Macrophage-Targeted LNP Development Challenges Do We Solve?

Macrophage-targeted LNPs must overcome several interconnected delivery barriers. A formulation may show strong particle uptake but insufficient functional payload expression, or accumulate in a target organ without reaching the intended macrophage population. We investigate lipid composition, ligand accessibility, macrophage biology, and intracellular delivery together to identify the factors limiting performance.

✔ Insufficient Macrophage-Targeted LNP Delivery and Off-Target Uptake

Conventional LNPs can undergo extensive hepatic uptake and interact with multiple phagocytic populations after systemic administration. Consequently, high total particle accumulation does not necessarily indicate efficient delivery to the intended macrophages. We compare ionizable lipid structures, helper lipid compositions, surface charge, PEG-lipid content, and targeting ligands to investigate these distribution patterns. Candidate formulations are evaluated using target-to-off-target cell uptake and functional expression measurements rather than relying only on total organ fluorescence.

✔ Variable LNP Uptake Across Macrophage Subsets and Activation States

Macrophage populations differ in receptor abundance, phagocytic activity, membrane composition, and intracellular trafficking. For example, CD206 expression can vary between tissue-resident macrophages and activated macrophage populations, while the commonly used M1/M2 classification does not fully represent the diversity of macrophage states in tissues. We select relevant macrophage models, compare receptor expression, and investigate ligand-dependent uptake across different cellular conditions. This helps identify whether a targeting strategy is suitable for the intended macrophage population rather than macrophages in general.

✔ PEG Shielding, Ligand Accessibility, and LNP Stability

PEG-lipids help maintain colloidal stability and influence interactions between LNPs and biological environments, but excessive surface shielding can reduce ligand accessibility and receptor recognition. Conversely, insufficient PEG coverage may affect particle stability and increase nonspecific interactions. We optimize PEG-lipid content, hydrophobic anchor structure, ligand spacer length, and surface density together. A 2026 HA-functionalized LNP study demonstrated that a formulation with 0.5% PEG-lipid showed improved uptake in activated macrophages compared with a 1.5% PEG-lipid formulation, illustrating the importance of balancing surface stabilization and ligand accessibility. Our LNP PEG-lipid optimization services support this type of formulation investigation.

✔ Limited Endosomal Escape and Payload Release from LNPs

Macrophages can internalize substantial amounts of nanoparticles through phagocytic and endocytic pathways, but internalization alone does not guarantee cytosolic payload availability. LNPs may remain trapped in endosomal or lysosomal compartments, resulting in limited mRNA translation or siRNA-mediated gene silencing. We investigate ionizable lipid pKa, helper lipid composition, membrane interactions, and intracellular trafficking to identify post-uptake limitations. Functional reporter expression, gene knockdown, and intracellular localization are evaluated together through our LNP endosomal escape evaluation services.

Facing Macrophage-Targeted LNP Delivery Challenges?

Tell us about your current lipid composition, targeting ligand, macrophage model, and delivery results. BOC Sciences can help investigate uptake limitations, ligand accessibility, particle stability, and intracellular payload release to establish a focused optimization strategy.

Applications of Macrophage-Targeted LNPs

Macrophages participate in tumor progression, inflammatory signaling, tissue repair, pathogen clearance, and lipid metabolism. Their ability to internalize nanoparticles makes them important targets for nucleic acid delivery and cellular reprogramming research. BOC Sciences supports customized LNP development for the following application areas, including targeting ligand selection, payload formulation, and functional delivery evaluation.

01

Tumor-Associated Macrophage Reprogramming

  • Macrophage Phenotype Modulation: Develop mRNA- or siRNA-loaded LNPs to investigate the regulation of tumor-associated macrophage functions. Potential payloads include transcription factors and signaling regulators associated with inflammatory activation and immunosuppressive macrophage states.
  • CAR-Macrophage Engineering: Explore macrophage-targeted mRNA delivery for transient expression of chimeric antigen receptors. A 2026 Nature Communications study investigated macrophage-targeted mRNA-LNPs for in situ CAR-macrophage programming and compared 36 CAR formats, demonstrating the potential of LNP-mediated macrophage engineering in tumor research.
  • Immunomodulatory Co-Delivery: Investigate combinations of CAR-encoding mRNA and selected immune agonists to modify macrophage activity within the tumor microenvironment. Mannose-functionalized LNPs and biomimetic PS-containing formulations provide relevant design directions for these applications.

Research reference: In situ programming of tailored CAR macrophages using mRNA-LNPs (Nature Communications, 2026).

02

Autoimmune and Chronic Inflammatory Disease Research

  • Inflammatory Signaling Regulation: Develop siRNA-loaded LNPs to investigate macrophage-associated inflammatory pathways, including NF-κB-related signaling and cytokine regulation. c-Rel and TAK1 are examples of research targets investigated using macrophage-directed lipid nanoparticle systems.
  • Activated Macrophage Targeting: Explore HA-functionalized LNPs for interactions with CD44-expressing activated macrophages. A 2026 study demonstrated that HA-functionalized LNPs with optimized PEG content could improve mRNA uptake in activated macrophages while maintaining transfection activity.
  • Macrophage Functional Modulation: Investigate mRNA or siRNA delivery to influence macrophage inflammatory responses, phagocytic activity, and selected immune-regulatory pathways. The intended response should be evaluated using both gene-expression and functional endpoints.

Research reference: DSPS-containing lipid nanoparticles for c-Rel siRNA delivery to immune cells (PLOS ONE, 2022); HA-functionalized LNPs for activated macrophage mRNA delivery (Biomacromolecules, 2026).

03

Pulmonary Infection and Lung Injury Research

  • Alveolar Macrophage Delivery: Develop macrophage-directed LNPs for delivering siRNA or mRNA to alveolar macrophages and other lung-associated phagocytic populations. Pulmonary administration can provide a local delivery approach, while antibody functionalization may add an additional cell-recognition mechanism.
  • Inflammatory Pathway Modulation: Investigate siRNA delivery against inflammatory regulators such as TAK1 to study macrophage-mediated cytokine production and tissue inflammatory responses.
  • Macrophage-Associated Tissue Repair: Explore mRNA delivery to investigate macrophage functions involved in inflammatory resolution, tissue repair, and pulmonary immune responses.

Research reference: F4/80-antibody-functionalized LNPs were developed for macrophage-targeted TAK1 siRNA delivery in a viral pneumonia model, with reported improvements in macrophage targeting and pulmonary inflammatory outcomes (Proceedings of the National Academy of Sciences, 2024).

04

Atherosclerotic Plaque Macrophage Targeting

  • Plaque Macrophage-Directed RNA Delivery: Develop mannose-functionalized or lipid-composition-engineered LNPs to investigate delivery to macrophages within atherosclerotic lesions. Targeting strategies can be selected according to plaque-associated receptor expression and the intended macrophage population.
  • Inflammatory Gene Silencing: Explore siRNA payloads targeting genes involved in macrophage inflammatory signaling and plaque-associated immune regulation, including SHP-1 and IRF5.
  • Macrophage Uptake Optimization: Compare particle composition, ligand density, and tissue distribution to improve delivery to plaque-associated macrophages while evaluating interactions with circulating monocytes and other vascular cells.

Research reference: Mannose-modified LNPs carrying SHP-1 siRNA were investigated for delivery to macrophages in atherosclerotic vulnerable plaques. In a mouse model, the piperazine-structured formulation achieved a reported M2 macrophage uptake efficiency of 46.32% (Nano Letters, 2026).

Develop Macrophage-Targeted LNPs for Your Research Application

Tell us your target macrophage population, tissue of interest, payload, and development requirements. BOC Sciences can help design, synthesize, formulate, and evaluate macrophage-targeted LNPs using suitable lipid and ligand engineering strategies.

Why Choose BOC Sciences for Macrophage-Targeted LNP Development?

Macrophage-Selective Lipid and Ligand Design

We connect macrophage receptor profiles, lipid composition, and ligand presentation to cellular delivery outcomes. Our development approach considers the differences between tissue-resident macrophages, activated inflammatory macrophages, and tumor-associated macrophages to support target-specific formulation design.

Comprehensive LNP Lipid and Raw Material Portfolio

In addition to customized development services, BOC Sciences provides LNP-related lipid raw materials and formulation components, including ionizable lipids, helper phospholipids, PEG-lipids, cholesterol-based components, and functional lipid materials. We help select suitable starting materials according to payload chemistry, targeting architecture, and formulation requirements, supporting projects that need both raw material supply and customized LNP development.

Specialized Lipid Materials and Surface Functionalization

Our capabilities cover lipid modification, ligand-lipid conjugate synthesis, antibody and peptide coupling, and carbohydrate functionalization. Through customized nanoparticle surface functionalization services and custom synthesis, we support the development of targeting components matched to specific macrophage populations.

Integrated Physicochemical and Biological Evaluation

Particle characterization, macrophage uptake analysis, intracellular localization, functional payload expression, and in vivo distribution can be incorporated into one development program. Our nanoparticle in vitro evaluation capabilities help connect formulation properties with cellular performance.

End-to-End Formulation Optimization and Development Support

From lipid and ligand selection to formulation, process optimization, characterization, and delivery evaluation, we organize the development workflow around your target macrophage population and payload requirements. Our LNP lipid library screening services support comparative candidate selection and iterative formulation development.

FAQs

What Are Macrophage-Targeted Lipid Nanoparticles?

Macrophage-targeted lipid nanoparticles (LNPs) are lipid-based delivery systems engineered to transport nucleic acids or other bioactive payloads preferentially into selected macrophage populations within specific tissues. Their targeting properties can be achieved through surface-functionalized ligands, such as mannose, antibodies, or peptides that recognize macrophage-associated receptors, or through lipid composition modifications that influence cellular interactions, protein-corona formation, and tissue distribution. Some formulations also incorporate biomimetic lipids, such as phosphatidylserine, to promote phagocyte recognition and uptake. Because macrophages differ in receptor expression and activation states, successful development requires evaluating both cell-specific uptake and functional payload delivery rather than relying solely on particle accumulation.

Several ligand types can be incorporated into LNP surfaces to improve interactions with selected macrophage populations. Mannose is commonly investigated for CD206-mediated recognition, while galactose-containing structures can interact with CD301-expressing cells. Antibodies against markers such as F4/80 in murine models, CD163, or CD206 provide additional receptor-recognition options. Folate and macrophage-binding peptides are also investigated for selected macrophage populations. Ligand selection should consider receptor abundance, species differences, and expression on non-target cells. BOC Sciences supports ligand synthesis, lipid conjugation, surface functionalization, and comparative evaluation of targeting architectures.

Macrophage-targeted LNPs are particularly suitable for delivering nucleic acid payloads, including mRNA, siRNA, and CRISPR-associated components. mRNA can support transient expression of immune-modulating proteins or cellular engineering factors, whereas siRNA can silence genes involved in inflammatory signaling, macrophage activation, and tumor-associated immunosuppression. Co-delivery of different RNA payloads can also be investigated when multiple biological pathways need to be modulated. For example, TAM-targeted LNP research has explored STAT3 and HIF-1α silencing, as well as mRNA-mediated macrophage reprogramming. BOC Sciences provides payload-compatible LNP formulation, encapsulation optimization, and functional delivery evaluation.

Evaluation should distinguish particle uptake, intracellular payload delivery, and functional biological activity. Physicochemical characterization includes particle size, PDI, zeta potential, morphology, and encapsulation efficiency. Cellular studies can compare LNP uptake across selected macrophage populations and other immune cells using fluorescence imaging and flow cytometry. Functional evaluation may include reporter expression, target-gene knockdown, and changes in macrophage-associated signaling. For studies, tissue distribution should be combined with cell-specific localization to determine whether LNPs reach the intended macrophage population. BOC Sciences integrates nanoparticle characterization, cellular uptake testing, and delivery evaluation.

Several factors can limit macrophage-targeted LNP performance. Off-target uptake by the liver, spleen, and other phagocytic cells may reduce delivery to the intended population. Macrophage heterogeneity and variable receptor expression can also cause inconsistent targeting across tissues and activation states. Furthermore, protein-corona formation may mask surface ligands, while excessive PEG-lipid content can reduce receptor accessibility. Even after cellular internalization, limited endosomal escape may prevent RNA payloads from reaching the cytosol. Addressing these challenges requires coordinated optimization of lipid composition, ligand density, particle stability, and intracellular delivery properties.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code